151 Background: Many medical oncologists avoid using the word "cure" even at 20 years post-diagnosis. Little data has been reported on oncologists' perceptions of patients’ residual risk of recurrence and their recommendations for follow-up care. Methods: E-mail requests were sent to oncologists to review four brief case scenarios and to indicate their perception of the patients’ residual risk of recurrence (Essentially Zero, 1-10%, 11-25%, 26-50%, 51-75%, 76-100%) and their recommended follow-up care. We also conducted a literature review to estimate actual recurrence risks for these stated scenarios. Results: 130 medical oncologists responded. The percentage who perceived a zero or essentially zero risk of recurrence steadily increased at the 5,10, 15, and 20+ year post-diagnosis time points in patients with Stage II triple negative breast, Stage II colon, Stage II lung, and Diffuse Large B-cell Lymphoma. Follow-up for 20+ years was recommended by 43%, 27%, 32%, and 38% of respondents respectively. Among respondents who recommended this long-term follow-up 37%, 63%, 57%, and 58% perceived no residual risk of recurrence after 20 years. There was no statistically significant relationship between recommending follow-up at > 20 years and the perception of the patient having a non-zero risk of recurrence. Even at twenty years post-diagnosis a > 10% risk of recurrence was expected by 14%, 8%, 10%, and 11% of respondents.However,a literature review indicated recurrence risks of < 5% after 10 years of disease free survival for patients with each described scenario. At 10 and 15 years, participants indicated the two most common reasons for follow up were screening for late and long-term effects followed by screening for new cancer Conclusions: The risk of cancer recurrence is typically greatest in the initial years after diagnosis and then decreases, especially after 10 years. In this study, many medical oncologists still perceived a > 10% residual risk of recurrence at 10, 15, and 20 years post-diagnosis and recommended follow-up visits.